This study investigates the effectiveness of combining an investigational medication with another treatment for patients with advanced non-small cell lung cancer (NSCLC) that has a specific gene mutation called epidermal growth factor receptor (EGFR). NSCLC is a type of lung cancer, and EGFR mutations can affect how cancer grows. The purpose of this study is to see if using both treatments together is better at controlling the cancer than using one treatment alone.

Participants in this study will receive either the investigational medication alone or in combination with another treatment. They will take these treatments by mouth, which means they will swallow pills. The study will monitor the effects of the treatments on the cancer and any side effects that may occur.

• Who can participate: Adults aged 18 or older with locally advanced or metastatic non-small cell lung cancer and an EGFR mutation can participate. They must be able to take pills by mouth and have not been treated with certain previous medications.
• Study details: Participants will take either the investigational medication alone or with another treatment. They will need to swallow pills as part of the study.